E,E,E-1-(4-Arylamino-4-oxo-2-butenoyl)-3,5-bis(arylidene)-4-piperidones: A topographical study of some novel potent cytotoxins

Bioorganic and Medicinal Chemistry

Volumn 15, Issue 17, 2007, Pages 5854-5865

  Jha, Amitabh ^a   Mukherjee, Chandrani ^a,b   Prasad, Ashok K ^b   Parmar, Virinder S ^b   Clercq, Erik De ^c   Balzarini, Jan ^c   Stables, James P ^d   Manavathu, Elias K ^e   Shrivastav, Anuraag ^f   Sharma, Rajendra K ^f   Nienaber, Kurt H ^f   Zello, Gordon A ^g   Dimmock, Jonathan R ^g  

^a ACADIA UNIVERSITY   (Canada)

^b UNIVERSITY OF DELHI   (India)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^e WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF SASKATCHEWAN   (Canada)

^g UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

3,5 Bis(arylidene) 4 piperidones; Cytostatic activity; Human N myristoyltransferase; Molecular modeling; Murine toxicity

Indexed keywords

1 [4 (3,4 DICHLOROPHENYL)AMINO 4 OXO 2 BUTENOYL] 3,5 BIS(4 NITROPHENYLIDENE) 4 PIPERIDONE; 1 [4 (3,4 DICHLOROPHENYL)AMINO 4 OXO 2 BUTENOYL] 3,5 BIS(PHENYLIDENE) 4 PIPERIDONE; 1 [4 (4 METHYLPHENYL)AMINO 4 OXO 2 BUTENOYL] 3,5 BIS(NITROPHENYLIDENE) 4 PIPERIDONE; 1 [4 (4 METHYLPHENYL)AMINO 4 OXO 2 BUTENOYL] 3,5 BIS(PHENYLIDENE) 4 PIPERIDONE; ANTINEOPLASTIC AGENT; CHEMICAL COMPOUND; CYTOTOXIN; MELPHALAN; PIPERIDONE DERIVATIVE; PROTEIN N MYRISTOYLTRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIFUNGAL ACTIVITY; ARTICLE; CANCER CELL; CELL LINE; CHEMICAL BOND; CONCENTRATION RESPONSE; CYTOTOXICITY; DRUG POTENCY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; MOLECULAR MODEL; MOUSE; MURINE LEUKEMIA; NEUROTOXICITY; NONHUMAN; T LYMPHOCYTE; TUMOR CELL LINE;

AMINATION; ANIMALS; CELL LINE; CELL SURVIVAL; CYTOTOXINS; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PIPERIDONES; STRUCTURE-ACTIVITY RELATIONSHIP;

HUMAN ECHOVIRUS 1; MURINAE; MUS;

EID: 34447329017     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2007.05.065     Document Type: Article

References (30)

1. Dimmock J.R., and Kumar P. Curr. Med. Chem. 4 (1997) 1
2. Dimmock J.R., Raghavan S.K., Logan B.M., and Bigham G.E. Eur. J. Med. Chem. 18 (1983) 248
3. Mutus B., Wagner J.D., Talpas C.J., Dimmock J.R., Phillips O.A., and Reid R.S. Anal. Biochem. 177 (1989) 237
4. Benvenuto J.A., Connor T.H., Monteith D.K., Laidlaw J.A., Adams S.C., Matney T.S., and Theiss J.C. J. Pharm. Sci. 82 (1993) 988
5. Dimmock J.R., Kumar P., Quail J.W., Pugazhenthi U., Yang J., Chen M., Reid R.S., Allen T.M., Kao G.Y., Cole S.P.C., Batist G., Balzarini J., and De Clercq E. Eur. J. Med. Chem. 30 (1995) 209
6. Rousseaux C.G., Townsend H.G., Phillips O.A., and Dimmock J.R. Fund. Appl. Toxicol. 14 (1990) 318
7. Dimmock J.R., and Taylor W.G. J. Pharm. Sci. 64 (1975) 241
8. Dimmock J.R., Arora V.K., Wonko S.L., Hamon N.W., Quail J.W., Jia Z., Warrington R.C., Fang W.D., and Lee J.S. Drug Des. Deliv. 6 (1990) 183
9. Dimmock J.R., Padmanilayam M.P., Puthucode R.N., Nazarali A.J., Motaganahalli N.L., Zello G.A., Quail J.W., Oloo E.E., Kraatz H.-B., Prisciak J.S., Allen T.M., Santos C.L., Balzarini J., De Clercq E., and Manavathu E.K. J. Med. Chem. 44 (2001) 586
10. a Prediction of Organic Acids and Bases (1981), Chapman and Hall, London 110-123
11. Dimmock J.R., Jha A., Zello G.A., Sharma R.K., Shrivastav A., Selvakumar P., Allen T.M., Santos C.L., Balzarini J., De Clercq E., Manavathu E.K., and Stables J.P. J. Enz. Inhib. Med. Chem. 18 (2003) 325
12. Selvakumar P., Lakshmikuttayamma A., Shrivastav A., Das S.B., Dimmock J.R., and Sharma R.K. Prog. Lipid Res. 46 (2007) 1
13. Suffness M., and Douros T. In: De Vita Jr. V.T., and Busch H. (Eds). Methods of Cancer Research, Volume XVI, Part A Vol. XVI (1979), Academic Press, New York 84
14. Lloyd A.W., and Smith H.J. In: Smith H.J. (Ed). Smith and Williams' Introduction to the Principles of Drug Design and Action. 3rd ed. (1998), Harwood Academic Publishers, Amsterdam 255
15. a Prediction for Organic Acids and Bases (1981), Chapman and Hall, London 110
16. Boyd M.R., and Paull K.D. Drug. Dev. Res. 34 (1995) 91
17. Althaus B. In: Herfindal E.T., and Gourley D.R. (Eds). Textbook of Therapeutics, Drug and Disease Management. 7th ed. (2000), Lippincott Williams and Wilkins, Philadelphia 1724
18. Remers W.A. In: Delgado J.N., and Remers W.A. (Eds). Wilson and Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry. 10th ed. (1998), Lippincott-Raven Publishers, Philadelphia 367
19. Peseckis S.M., and Resh M.D. J. Biol. Chem 269 (1994) 30888-30892
20. King M.J., and Sharma R.K. Anal. Biochem. 199 (1991) 149-153
21. Paull K.P., Shoemaker R.H., Hodes L., Monks A., Scudiero D.A., Rubinstein L., Plowman J., and Boyd M.R. J. Natl. Cancer Inst. 81 (1989) 1088-1092
22. Jha A., and Dimmock J.R. Synth. Commun. 33 (2003) 1211-1233
23. MacroModel, Version 8.0, Department of Chemistry, Columbia University, New York, April 2002.
24. Hansch C., and Leo A.J. Substituent Constants for Correlation Analysis in Chemistry and Biology (1979), John Wiley and Sons, New York 49-50
25. a Prediction for Organic Acids and Bases (1981), Chapman and Hall, London 111
26. Statistical Package for the Social Sciences, SPSS 12.0 for Windows, Release 12.0.0, SPSS Inc., Chicago, IL, 2003.
27. Balzarini J., De Clercq E., Mertes M.P., Shugar D., and Torrence P.F. Biochem. Pharmacol. 31 (1982) 3673-3682
28. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi: approved standard M38-A. National Committee for Clinical Laboratory Standards, Wayne, PA, 2002.
29. Stables J.P., and Kupferberg H.J. In: Avanzini G., Tanganelli F., and Avoil M. (Eds). Molecular and Cellular Targets for Antiepileptic Drugs (1997), John Libbey and Company Ltd, London 191-198
30. Dunham M.S., and Miya T.A. J. Am. Pharm. Ass. Sci. Ed. 46 (1957) 208-209